Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HER2/neu expression in malignant lung tumors.

Fred R Hirsch1, Wilbur A Franklin, Robert Veve

  • 1Lung Cancer Program, Department of Pathology, University of Colorado Cancer Center, Denver, CO 80262, USA.

Seminars in Oncology
|March 15, 2002
PubMed
Summary

Trastuzumab shows potential for treating non-small cell lung cancer (NSCLC) by targeting HER2/neu. While HER2/neu expression varies in NSCLC, further studies are needed to confirm trastuzumab

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer.

Cancer research·2026
Same author

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Mitochondrial DNA in Lung Cancer: from biology to clinical implications.

Critical reviews in oncology/hematology·2026
Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Lung Cancer in Never Smokers: Genetics, Epidemiology, Environmental Exposures, and Distinct Immune Landscape.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer has a poor prognosis despite treatment.
  • Trastuzumab, a HER2/neu-targeting antibody, is effective in metastatic breast cancer.
  • HER2/neu expression in non-small cell lung cancer (NSCLC) warrants investigation.

Purpose of the Study:

  • To evaluate the potential of trastuzumab for treating NSCLC.
  • To characterize HER2/neu expression in NSCLC tumors.
  • To determine the role of HER2/neu in NSCLC pathogenesis.

Main Methods:

  • Immunohistochemistry (HercepTest) to assess HER2/neu protein expression.
  • Fluorescence in situ hybridization (FISH) to evaluate HER2/neu gene amplification.
  • Analysis of HER2/neu expression across different NSCLC subtypes.

Related Experiment Videos

Main Results:

  • 25% of NSCLC tumors showed 2+ or greater HER2/neu expression.
  • Only 6-8% of NSCLC tumors exhibited 3+ HER2/neu overexpression.
  • HER2/neu expression was more common in adenocarcinomas than other NSCLC types.
  • HER2/neu gene amplification was less frequent in NSCLC compared to breast cancer; polysomy was the main cause of increased expression.

Conclusions:

  • HER2/neu is expressed in a subset of NSCLC, particularly adenocarcinomas.
  • Polysomy, not gene amplification, is the primary driver of elevated HER2/neu in NSCLC.
  • Prospective studies with trastuzumab in NSCLC are ongoing.
  • Combined immunohistochemistry and FISH analysis are crucial for identifying clinically relevant HER2/neu-positive NSCLC.